From PsychonautWiki
Jump to: navigation, search

This article requires proofreading.

As such, it may contain incorrect grammar, spelling, or punctuation.

Summary sheet: MCPP
Molecular structure of mCPP
Chemical Nomenclature
Common names mCPP
Substitutive name meta-Chlorophenylpiperazine
Systematic name 1-(3-chlorophenyl)piperazine
Class Membership
Psychoactive class Stimulant
Chemical class Piperazine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 15 - 20 mg
Light 20 - 50 mg
Common 50 - 120 mg
Strong 120 - 150 mg
Heavy 150 mg +
Onset 20 - 60 minutes
Peak 2 - 4 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

meta-Chlorophenylpiperazine (also known as mCPP) is a stimulant drug of the phenylpiperazine class. It was first synthesized as one in a series of potential novel antihistamines by Thomas H. Wicker Jr. in 1951 as part of his doctoral work at the University of Florida. [1] Unlike many other stimulants like amphetamine, mCPP is generally considered to be unpleasant. mCPP is notable for inducing anxiety[2], and causing migraines and severe headaches.[3] mCPP is occasionally encountered as an adulterant in street MDMA.[4]



This chemistry section is incomplete.

You can help by adding to it.

mCPP is a drug in the phenylpiperazine class. On the meta-position of the phenyl group, there is a chlorine atom.


mCPP acts as an agonist at the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3 and 5-HT7 receptors, as well as inhibiting the serotonin transporter.[5]. Substances that act at the 5-HT2B receptor, most notably fenfluramine, can cause significant heart problems which can be fatal in some individuals.[6] mCPP's action at the 5-HT2A receptor may explain its psychedelic-like effects.

mCPP is an active metabolite of the antidepressant trazodone.[7]

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Cognitive effects

Visual effects

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding upon or correcting it.
We also recommend that you practice diligent independent research and the most thorough harm reduction practices when using this substance.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

mCPP is not known to be addictive, but there are not any studies exclusively on its addiction potential.

Dangerous interactions

mCPP is metabolized by cytochrome P450 2D6[8], and concurrently taking inhibitors of that enzyme results in increased serum levels of mCPP. Commonly encounter inhibitors of CYP2D6 include ciprofloxacin, bupropion (Wellbutrin), fluoxetine (Prozac) and grapefruit juice.[9]

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Serotonin syndrome risk

Combinations in the list below may increase the amount of neurotransmitters such as serotonin and dopamine to dangerous or even fatal levels.

Legal issues


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Austria: Since January 1, 2012, mCPP is illegal to possess, produce and sell under the NPSG. (Neue-Psychoaktive-Substanzen-Gesetz Österreich)
  • United Kingdom - mCPP is a Class C, Schedule 4 (Part 1) drug in the United Kingdom.[12]
  • United States - mCPP is unscheduled in the United States, but could be considered an analogue of benzylpiperazine if it is sold for human consumption.
  • Switzerland - mCPP is illegal in Switzerland.[13]
  • China - As of October 2015 mCPP is a controlled substance in China.[14]

See also

External links


  1. Wicker, Thomas H. (1951) Derivatives of Piperazine. XII. Synethesis of 1-Arylpiperazines and Amino Acid Derivatives. Retrieved from University of Florida Theses & Dissertations Collection. alphbibnum: 000554269 |
  2. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. |
  3. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study. |
  4. mCPP: an undesired addition to the ecstasy market |
  5. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. |
  6. Drugs and Valvular Heart Disease |
  7. 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole |;jsessionid=9006CB66248FC2F30E99D5AEAB847661.f04t01
  8. Human CYP2D6 and metabolism of m-chlorophenylpiperazine |
  9. P450 Drug Interaction Table |
  10. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441.
  11. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441.
  12. Home Office Controlled Drugs |
  14. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.